BEOVU
BEOVU (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor. It is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). The medication serves a therapeutic role in managing these ocular conditions by targeting specific pathways involved in vascular growth and fluid leakage.
How BEOVU Works
Brolucizumab functions by binding to the three major isoforms of vascular endothelial growth factor A (VEGF-A), including VEGF 110, VEGF 121, and VEGF 165. This binding prevents VEGF-A from interacting with its receptors, VEGFR-1 and VEGFR-2. By inhibiting these interactions, the drug suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Details
- Status
- Prescription
- First Approved
- 2019-10-07
- Routes
- INTRAVITREAL
- Dosage Forms
- INJECTABLE
BEOVU Approval History
What BEOVU Treats
2 indicationsBEOVU is approved for 2 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Diabetic Macular Edema
BEOVU Target & Pathway
ProTarget
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pathway Context
VEGFR on blood vessels is activated by VEGF to promote angiogenesis
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
BEOVU Competitors
Pro2 other drugs also target VEGFR. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGFR). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to BEOVU
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BEOVU FDA Label Details
ProIndications & Usage
FDA Label (PDF)BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Diabetic Macular Edema (DME) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.